Breakingviews - Takeda feeling uncomfortable Shire side effects
Takeda Pharmaceutical is showing signs of recovery after a mega-merger, but shareholders keep feeling the pain. Some 18 months after completing a $62 billion takeover of Irish rival Shire, the Japanese drugmaker may sell another business to further pare debt. Promised cost savings are also materialising. A weak stock performance, however, suggests Chief Executive Christophe Weber overpaid.